TULA DUAL: Trans Urethral Laser Ablation of recurrent bladder tumors in outpatient setting.

Arch Ital Urol Androl

IRCCS Ospedale Policlinico San Martino, Genova, Italy; Department of Surgical and Diagnostic Integrated Sciences (DISC), University of Genova, Genova.

Published: February 2023

To the Editor, Bladder cancer (BCa) is the second most common cancer in urological clinical practice, after prostate adenocarcinoma. Usually occurs in patients between 60 and 70 years old, three times more frequently in men than women. About 75% of bladder cancer are pTa or pT1, even more frequently considering a population younger than 40 years old. Early detection is of paramount importance since allows to find tumors when they are still superficial and therefore with a better prognosis.

Download full-text PDF

Source
http://dx.doi.org/10.4081/aiua.2023.11171DOI Listing

Publication Analysis

Top Keywords

bladder cancer
8
tula dual
4
dual trans
4
trans urethral
4
urethral laser
4
laser ablation
4
ablation recurrent
4
recurrent bladder
4
bladder tumors
4
tumors outpatient
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!